Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide

作者：Larocca Alessandra; Cavallo Federica; Bringhen Sara; Di Raimondo Francesco; Falanga Anna; Evangelista Andrea; Cavalli Maide; Stanevsky Anfisa; Corradini Paolo; Pezzatti Sara; Patriarca Francesca; Cavo Michele; Peccatori Jacopo; Catalano Lucio; Carella Angelo Michele; Cafro Anna Maria; Siniscalchi Agostina; Crippa Claudia; Petrucci Maria Teresa; Ben Yehuda Dina; Beggiato Eloise; Di Toritto Tommaso Caravita; Boccadoro Mario; Nagler Arnon; Palumbo Antonio^*

来源：Blood, 2012, 119(4): 933-939.

DOI：10.1182/blood-2011-03-344333

Lenalidomide plus dexamethasone is effective in the treatment of multiple myeloma (MM) but is associated with an increased risk of venous thromboembolism (VTE). This prospective, open-label, randomized substudy of a phase 3 trial compared the efficacy and safety of thromboprophylaxis with low-dose aspirin (ASA) or low-molecular-weight heparin (LMWH) in patients with newly diagnosed MM, treated with lenalidomide and low-dose dexamethasone induction and melphalan-prednisone-lenalidomide consolidation. Overall, 342 patients who did not have clinical indications or contraindications to antiplatelet or anticoagulant therapy were randomly assigned to receive ASA 100 mg/d (n = 176) or LMWH enoxaparin 40 mg/d (n = 166). The incidence of VTE was 2.27% in the ASA group and 1.20% in the LMWH group. Compared with LMWH, the absolute difference in the proportion of VTE was 1.07% (95% confidence interval, -1.69-3.83; P = .452) in the ASA group. Pulmonary embolism was observed in 1.70% of patients in the ASA group and none in the LMWH group. No arterial thrombosis, acute cardiovascular events, or sudden deaths were reported. No major hemorrhagic complications were reported. In previously untreated patients with MM receiving lenalidomide with a low thromboembolic risk, ASA could be an effective and less-expensive alternative to LMWH thromboprophylaxis. This study was registered at www.clinicaltrials.gov as #NCT00551928. (Blood. 2012;119(4): 933-939)

• 出版日期2012-1-26